Loading…
Loading…
GENPF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GENPF and 80,000+ other tickers.
See exactly how GENPF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GENPF and 80,000+ other tickers.
Genix Pharmaceuticals Corporation, established in 1993 and headquartered in Vancouver, Canada, is actively involved in the creation, production, licensing, and distribution of various life science products. The company's primary focus in the Canadian market is on nutraceuticals and pharmaceuticals. Their product pipeline features several key developments: Flu-X: An herbal treatment available as an oral solution or spray, targeting viral infections, influenza, and coronaviruses responsible for common colds. Renochlor: A nutritional supplement formulated to support the revitalization and…
Vancouver, British Columbia, May 5, 2026 - TheNewswire – Genix Pharmaceuticals Corporation (TSX-V: GENX) (“Genix” or the “Company”) announces the resignation of Mr. Danny Lee as Chief Financial Officer, effective April 30, 2026, to focus on his other business obligations. On behalf of the Genix team, we thank Mr. Lee for his valuable contributions to the Company since December 2020, and wish him continued success in his future endeavours.
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") wishes to clarify an error in its news release dated September 04, 2025 , regarding the Company's recently closed non-brokered private placement. The previous release incorrectly stated that the Units were issued at a price of $0.10 per Unit.
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") announces that it has closed its previously announced non-brokered private placement raising gross proceeds of $100,000. The Company has issued 2,000,000 units (each a "Unit") at a price of $0.10 per Unit.
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that pursuant to its news release of January 18, 2024, the TSX Venture Exchange has approved the Company's application to amend both the exercise price and the warrant accelerator terms, in addition to extending the expiry dates of 3,354,945 previously issued and outstanding warrants (the "Warrants"). The current exercise price of the Warrants will be reduced from $0.30 per warrant share to $0.15 per warrant share.
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has made an application to the TSX Venture Exchange (the "Exchange") to amend the exercise price, the warrant accelerator terms and extend the expiry date of 3,354,945 previously issued and outstanding warrants (the "Warrants"). The Corporation is proposing to reduce the exercise price of the warrants from $0.30 per warrant share to $0.15 per warrant share.